logo.png
Corbus Pharmaceuticals Reports First Quarter 2021 Financial Results and Provides Corporate Updates
13 mai 2021 08h05 HE | Corbus Pharmaceuticals Holdings, Inc.
Phase 3 study of lenabasum in dermatomyositis on schedule for topline data in Q2 2021 Company focused on advancing cannabinoid programs in metabolic diseases and cancer into the clinic in 2022Corbus...